Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Fanconi's Anemia
Primary Purpose
Fanconi's Anemia
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
cyclophosphamide
Allogeneic Bone Marrow Transplantation
Sponsored by
About this trial
This is an interventional treatment trial for Fanconi's Anemia focused on measuring Fanconi's Anemia, aplastic anemia, hematologic disorders, rare disease
Eligibility Criteria
Diagnosis of severe aplastic anemia with the typical phenotype of Fanconi's anemia: Short stature Hypoplastic radii Skin pigmentation Renal anomalies Chromosomal fragility Family history of Fanconi's anemia Histocompatible related donor No evidence of excessive in vitro chromosome fragility typical of Fanconi's anemia Normal CBC and bone marrow
Sites / Locations
- Fairview University Medical Center
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00005891
First Posted
June 2, 2000
Last Updated
June 23, 2005
Sponsor
Fairview University Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT00005891
Brief Title
Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Fanconi's Anemia
Study Type
Interventional
2. Study Status
Record Verification Date
July 2004
Overall Recruitment Status
Completed
Study Start Date
March 2000 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Fairview University Medical Center
4. Oversight
5. Study Description
Brief Summary
OBJECTIVES:
I. Determine the effectiveness of moderate dose cyclophosphamide and total lymphoid radiotherapy in terms of improving the survival and reducing the morbidity following allogeneic bone marrow transplantation in patients with Fanconi's aplastic anemia.
Detailed Description
PROTOCOL OUTLINE: Patients receive cyclophosphamide IV over 2 hours on day -6 through -3 and total lymphoid radiotherapy on day -1. Patients undergo allogeneic bone marrow transplantation on day 0.
Patients are followed for at least 100 days.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fanconi's Anemia
Keywords
Fanconi's Anemia, aplastic anemia, hematologic disorders, rare disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
cyclophosphamide
Intervention Type
Procedure
Intervention Name(s)
Allogeneic Bone Marrow Transplantation
10. Eligibility
Sex
All
Minimum Age & Unit of Time
0 Years
Maximum Age & Unit of Time
54 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Diagnosis of severe aplastic anemia with the typical phenotype of Fanconi's anemia: Short stature Hypoplastic radii Skin pigmentation Renal anomalies Chromosomal fragility
Family history of Fanconi's anemia
Histocompatible related donor No evidence of excessive in vitro chromosome fragility typical of Fanconi's anemia Normal CBC and bone marrow
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniel J. Weisdorf
Organizational Affiliation
Fairview University Medical Center
Official's Role
Study Chair
Facility Information:
Facility Name
Fairview University Medical Center
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Fanconi's Anemia
We'll reach out to this number within 24 hrs